Kardium, headquartered in United States, remains privately held. The latest valuation stands at $1B. Its shares do not trade on a public exchange.
One company valuation: $1B, dated Aug 2026.
Qatar Investment AuthorityLEADMMMCAPPPiper Heartland Healthcare CapitalEEventide Asset ManagementEEckuity Capital
T. Rowe Price
Durable Capital PartnersQatar Investment AuthorityKardium is a privately held medical solutions company advancing the treatment of atrial fibrillation. Guided by the belief that every detail matters, it develops integrated technologies that give physicians greater control over therapy delivery. Founded in 2007 and headquartered in Vancouver, Canada, Kardium is a rapidly growing company recognized as one of the top places to work in British Columbia.
Its flagship product, the Globe Pulsed Field System, is the only integrated, high-density cardiac mapping and ablation system that enables single-shot pulmonary vein isolation using a single catheter, serving cardiologists treating patients with atrial fibrillation. The system received U.S. Food and Drug Administration approval on September 3, 2025.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Kardium.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Kardium availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Kardium included.
The routes section explains what is realistically available for a company at this stage.
No. Kardium is a private company; its shares do not trade on a public exchange.
The last valuation is $1B.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
